RLMD - Relmada Therapeutics, Inc. Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Relmada Therapeutics (RLMD) is developing innovative intravenous treatments for major depressive disorder, while the asset's market price remains decoupled from sales. Finances are based on clinical trial expenditures without positive cash flow. This EV/EBITDA valuation chart is fixed at 0.00. The brand is rapidly gaining authority in psychiatry by offering advanced therapies for CNS disorders with prolonged effects.
Metric breakdowns and analytics for relmada.com (RLMD)
- market price and analyst price targets:
- market capitalization statistics:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Relmada Therapeutics|RLMD - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Relmada Therapeutics, Inc.|RLMD - Aggregate Debt Obligations|Debt to Book Value Relmada Corp|RLMD - Amount of Long-Term Liabilities|Company Short-Term Debts Relmada Therapeutics|Quick Ratio relmada.com
- financial results and valuation multiples details:
RLMD - Company Net Income|Expected Profit Relmada Therapeutics|RLMD - Company Value to Net Income|Forward P/E Multiple Relmada Therapeutics|RLMD - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Corp|RLMD - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Relmada Therapeutics|RLMD - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months relmada.com|RLMD - Earnings growth in current year|Expected earnings per share growth for next year Relmada Therapeutics
Summary company analysis:Relmada (RLMD)
Outsourcing production and testing minimizes capital expenditures for Relmada Therapeutics (RLMD), allowing the company to maintain high operational flexibility. The current Enterprise Value to EBITDA ratio 0.00 reflects the relationship between the total market value of the business and its EBITDA, helping investors assess the level of debt load and the fundamental overvaluation of the asset relative to its ability to generate cash flow.
Competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Neurocrine Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|axsome.com (AXSM) - Enterprise Value to EBITDA Ratio|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. (XENE) - EV/EBITDA Multiple|VKTX (Viking Pharma) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus Corp)|EV/EBITDA Multiple CPRX|EV/EBITDA Multiple denalitherapeutics.com (DNLI)|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|AMLX: Enterprise Value to EBITDA Ratio|Trevi Corp - Enterprise Value to Operating Income Before Depreciation Ratio|PRAX: EV/EBITDA Multiple|anavex.com - Business Value to Operating Income Before Depreciation|CBLL (CeriBell) - EV/EBITDA Multiple|Company Value to EBITDA Prothena Corporation PLC PRTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX (Annexon Biosciences Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMER (Omeros)|EV/EBITDA Multiple neurogene.com NGNE|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Company Value to EBITDA Scilex Holding Company, Inc. (SCLX)|Enterprise Value to EBITDA Ratio TVGN|EV/EBITDA Multiple Alpha Cognition Corp|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio IKT|EV/EBITDA Multiple SAVA (Cassava)|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|Coya - EV/EBITDA Multiple|Vistagen Therapeutics (VTGN) - Enterprise Value to EBITDA Ratio|ovidrx.com (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABOS - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|ATHE: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PEPG (pepgen.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|ANVS - Enterprise Value to EBITDA Ratio|Grace Tx - EV/EBITDA Multiple|AIFF (Firefly Neuro) - Enterprise Value to Operating Income Before Depreciation|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation NRSN|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA MetaVia, Inc. MTVA|Enterprise Value to EBITDA Ratio NRXS (NeurAxis, Inc)|EV/EBITDA Multiple heliusmedical.com (HSDT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Business Value to Operating Income Before Depreciation NEUP|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Athira Pharma Inc|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Alzamend Neuro - Business Value to Operating Income Before Depreciation|CYCN (Cyclerion Therapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Protagenic PTIX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CRGT (cortigent.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI - Enterprise Value to EBITDA Ratio|Cara Therapeutics, Inc. - EV/EBITDA Multiple|CHRO - EV/EBITDA Multiple|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|LBPH (Longboard Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Marinus Pharma|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SNPX (Synaptogenix Inc.)|Trevena, Inc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|WENA: EV/EBITDA Multiple|Company Value to EBITDA cerevel.com (CERE)
